Bloomsbury Genetic Therapies (Bloomsbury GTX)
Biotechnology company developing potentially curative gene therapy treatments for patients suffering from rare neurological and metabolic diseases with high unmet medical need.
Notes
Bloomsbury Genetic Therapies (Bloomsbury GTX) is a UK-based biotechnology company focused on developing gene therapies for rare neurological and metabolic diseases. The company aims to provide potentially curative one-time treatments for patients who currently have limited or no treatment options.
The company's pipeline targets devastating rare diseases where gene therapy has the potential to address the underlying genetic cause and transform patient outcomes. Bloomsbury GTX leverages advanced gene therapy vectors and delivery technologies to develop safe and effective treatments.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Focus on rare neurological diseases
- Focus on rare metabolic diseases
- Gene therapy approach for genetic diseases
- Potentially curative one-time treatments
- London/UK-based company
- Targeting diseases with high unmet medical need
- Advanced gene therapy vector technology
Sources
- Company disclosures and press releases
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| AlbionVC (Healthcare) | London, UK | biotech-focused | seedseries-a+1 | 17 |